List of Artificial Intelligence Companies in Germany - 27

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

With over 30 years of experience, Alcedis combines medical expertise with ground-breaking technologies to pioneer data-driven clinical research. Our module-based service concept and flexible data capture systems adapt seamlessly to any project structure and accompany your entire research process - from Phase I to drug approval and beyond market access into real-world evidence.

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG.

BIOTYPE is an innovative German solution provider for molecular precision diagnostics. We are committed to advancing precision medicine through our products & services for reliable analysis and interpretation of clinical biomarkers. BIOTYPE offers a strong portfolio in molecular cancer diagnostics for applications in hemato-oncology, liquid biopsy, and molecular profiling of solid tumors. The portfolio includes IVD assays for clinical diagnostics and RUO assays for translational and clinical research. In addition, BIOTYPE offers high-quality and IVD-compliant contract development and manufacturing services. Our proprietary MODAPLEX platform is a benchtop system for automated molecular profiling and multi-biomarker testing. MODAPLEX addresses the growing need to simplify and accelerate precision testing by reliably delivering actionable molecular information required for biomarker-guided care in precision medicine. The MODAPLEX consolidates multi-gene testing into one workflow with same-day results. BIOTYPE‘s quality management system is certified according to ISO 9001:2015 & ISO 13485:2016.

At ColVisTec, we work with the world's leading manufacturers in the paint, pharmaceutical, plastics, and chemical industries. Our team of highly knowledgeable engineers and scientists support them with a reliable and industry-ready inline UV-Vis spectroscopy.​ ​ By adding inline UV-Vis spectrophotometry devices onto the assembly line, we can measure the production output in real-time. In addition, it opens fantastic opportunities for productivity as well as quality gains, leading to a huge stand-alone benefit for your factory when implemented into the context of digitalized manufacturing: Industry 4.0. Our technology can be customized for a wide variety of processes, allowing flexible hardware configurations, offering data output in different formats, and excellent integration with the software solutions already in place. We take pride in our extensive customer support and provide a full menu of training options to secure a smooth transition from off-line measurement to fully automated inline solutions. ​ From our headquarters in Berlin, Germany, we support our product line worldwide and work in close cooperation with other process machinery manufacturers to provide complete solutions when customers are in the market for new plants. Most often our technology is fitted to the existing manufacturing facilities, boosting their productivity and quality. We don’t see ourselves as suppliers of hardware, our aim is to provide unique solutions that are specifically required by your process. ​ Our company was founded in 2009 and is now co-funded by the Horizon 2020 program of the European Union.

Computomics was founded to bring the latest bioinformatics discoveries to industry application, facilitating global agricultural development.Crops: Parse large genomic data sets for plant breeders, deliver breeding recommendations, and provide molecular biology insight to reduce crop area requirements.Animal Health: Assemble and annotate genomic data from your species of interest, compare time-series data and visualize genomic variation in insightful ways.Metagenomics and Microbial Genomics: Analyze complex microbial communities and discover new organisms and metabolic pathways in a variety of samples.

Differential Bio is integrating scale-down experiments with AI-based modeling to optimize how industry-relevant microbes grow ("biomass fermentation") and produce ("precision fermentation"). By optimizing bioprocesses and growth conditions, the company is not only increasing their clients' R&D efficiency but alsodramatically improving bioproduction outcomes such as yield, cost efficiency, and product quality.

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.

Fraunhofer is EuropeÕs largest application-oriented research organization. Our research efforts are geared entirely to peopleÕs needs: health, security, communication, energy and the environment. As a result, the work undertaken by our researchers and developers has a significant impact on peopleÕs lives. We are creative. We shape technology. We design products. We improve methods and techniques. We open up new vistas. In short, we forge the future.

Heinrich Heine University Düsseldorf is a Higher Education institution that offers a wide range of academic programs and research opportunities.

Hummingbird extracts deep insights into disease through the integrated analysis of both disease and immune system derived small RNA biomarkers from whole blood. This dual interrogation of signal from disease and the host response to disease enables a highly sensitive, robust, and AI powered platform that will revolutionize how we diagnose, treat, and manage cancer and other diseases.

Your partner for nucleic acid extraction, biobanking, genotyping, epigenetics, transcriptomics, NGS, proteomics and bioinformatics.

Lifespin GmbH, a deep data company developing a proprietary AI-based health testing platform to measure quantitative metabolic data in patient samples. Our platform is based on mapping metabolomics for human health and translating that data into health information that can be deployed in a wide range of pharmaceutical, research, and clinical settings. Lifespin's health diagnostics software will be applicable in the broader healthcare space ranging from diagnostics to patient stratification and personalized medicine, as well as supporting the drug discovery process.

The Max Planck Institute of Quantum Optics is a forefront research organizations in the fields of quantum physics and photonics, with light-matter interaction at its core. In five different research areas excellent scientists from all corners of the world are working together in an open and diverse environment, breaking the ground to what could become another revolution in science. Our laboratories are amongst the best equipped in the world and our scientific culture and spirit is based on freedom and trust, both allowing our scientists to reach the most ambitious objectives.

Mindpeak's mission is to enable personalised cancer treatment through AI tissue diagnostics Our partners are leading pathology and university labs. Our team consists of world-class industry experts in machine learning and company building. Mindpeak's Impact The demand for medical image analysis is growing rapidly but the number of cancer experts remains the same - this results in growing workloads per specialist. We help cancer experts meet this challenge. We build automation tools for visual diagnosis using state-of-the-art artificial intelligence and deep learning. Our tools assist cancer experts in providing reliable and reproducible diagnoses. This frees specialists from tedious, repetitive tasks such as quantification of cells or biomarkers and allows them to focus on tasks where their human expertise is indispensable.

MSAID transforms the way scientists analyze proteomics data. MSAID is a bioinformatics spin-off from the Technical University of Munich, Germany and is located at the high-tech-center gate, which is part of the TUM campus in Garching. The company was founded by an interdisciplinary team of scientists with the vision to provide better computational solutions to the field of proteomics. The team has an exceptionally strong track record and long-standing expertise in the acquisition, analysis, and interpretation of proteomic data. Our ambition is to replace current algorithms for proteomics with powerful, AI-based solutions, thereby paving the way for a smarter, deeper, and more reliable way of interrogating proteomic data. Legal Notice: https://www.msaid.de/legal-notice

Noah Labs develops AI-based software solutions for medical care and research to facilitate diagnosis, manage conditions, and guide intervention.

At Nostos Genomics, we partner with genetic testing labs to turn data into genomic insights and give more people with genetic diseases a fast and clear diagnosis. Over 300 million people live with a rare genetic disease and for most, the journey from the first symptoms to a diagnosis takes more than 5 years. Even after that, diagnoses are often incorrect, and many people end up not being diagnosed at all. Now, new technology is allowing millions to benefit from genetic testing for diagnosis, while at the same time targeted therapies for previously untreatable disorders are being developed. But the last step in genetic testing – interpreting mutations – remains laborious and costly. It can take a genetic testing lab weeks to interpret data from a single patient. Because of limited understanding of the consequences of mutations, the test results are often inconclusive and leave 70% of people undergoing a genetic test without diagnosis. Our CE-certified platform leverages a unique combination of machine learning and synthetic biology to characterize mutations at scale and automate the interpretation. By offering it to labs, we enable them to diagnose more people in a fraction of the time.

Omiqa is a contract research organisation, specialising in providing efficient bioinformatics solutions to support life scientist. Our expertise spans from conducting cutting-edge research and developing large-scale bioinformatic workflows to creating custom graphical web and desktop applications.

Origenis - We cure diseases with novel small molecule drugs where no drugs have been discovered yet. We create synergistic small molecule drug pipelines.

Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to advance Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling. We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). scioDiscover is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. Our team is dedicated to supporting you throughout your project: Project Planning: From planning to execution, we will help you navigate the most efficient route to achieve your research objectives. Technical Expertise: Our team provides unmatched proficiency in your proteomic analysis endeavors. Customized Solutions: We provide customized solutions to meet your specific research needs. Comprehensive Study Report: Our services include a comprehensive data analysis and a customized report. Our Platform Is Used For: • Protein Biomarker Identification and Verification • Novel Drug Target Discovery • Mode-of-Action Analysis • Pathway Activity Analysis • Disease Model Characterization, among other key applications Join us on our mission to revolutionize medicine! #PrecisionMedicine #Proteomics

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company addressing high unmet medical needs in the areas of immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies for challenging or currently undruggable targets. With over 15 development programs focusing on targets in indications where antisense-based approaches have clear benefits over other therapeutic modalities, Secarna is the leading European antisense drug discovery and development company.

[INTRODUCING OUR COMPANY] The people of Seegene are on a purposeful mission to improve the world we live in. We aim to improve the quality of life for everyone globally by bringing molecular diagnostics to the masses. Molecular diagnostics is the most effective method to accurately diagnose ailments and is also the best way to diagnose them early which is when you can make the most difference in the recovery treatment. With industry-leading IP in molecular diagnostics reagent assays, we are dedicated to leveraging our unique technologies to increase our product portfolio, expand our market coverage, and lowering the total cost to serve our customers so that molecular diagnostics become a part of the fabric of everyone’s life and thus, improving the quality of life for everyone in the world. [OUR HISTORY AND OUR FUTURE] Since our founding in 2000, we have been steadfastly focused on molecular diagnostics. Currently, our product portfolio consists of over 250 molecular diagnostics reagent kits as well as a wide range of instruments and consumables that are sold globally. Testament to our expertise, when the pandemic started, Seegene was one of the first companies in the world to provide testing kits that were crucial in the fight against COVID. Today, we are a company with revenue of over $1 billion dollars and 65% gross margins. With 8 overseas entities, we generate a majority of our revenue outside of Korea. In keeping with our spirit of innovation and making a difference in the world, there are many exciting innovations being worked on at Seegene which will make it easier for the world to access the benefits of molecular diagnostics. We are transforming our business from a discrete reagent assay and instruments business to a platform business that will create new markets for molecular diagnostics and improve the quality of life for everyone. We hope that you will join us in our mission to make a meaningful difference in the world.

Serving ~1,900 clinical sites globally, TeraRecon, a ConcertAI company, is a Best in KLAS solution provider for AI-empowered radiology, oncology, cardiology, neurology, and vascular surgery. Awarded the KLAS Category Leader for Advanced Visualization, TeraRecon solutions are independent of any one manufacturer's imaging equipment or PACS system, allowing a single, unified, and simplified clinical workflow that can improve efficiencies and deliver actionable physician-guided insights.

Unlocking tRNA modifications for drug development

Better breast cancer screening should be a universal offering to every woman in the world. Vara’s AI-powered software platform, created with screening radiologists within the German Mammography Screening Programme, mitigates much of the human subjectivity associated with reading mammography results—and reduces the repetitive work screening physicians are routinely subjected to. Vara’s full-stack platform manages all processes within a screening centre and makes breast cancer screening more effective, more measurable, and more accessible for everyone, everywhere. By democratising access to early screening around the world, we deliver measurable impact backed by clinical evidence. We are partnering globally, to deliver breast cancer screening where it is needed most.

YUMAB Company profile The German biotech company YUMAB was founded in 2012 as spin-off the University of Braunschweig. In little more than five years, YUMAB (a phonetic play on “HUMAB”, which stands for “human monoclonal antibody and in which the “Y” symbolizes the well-known antibody structure) has become a global player in human monoclonal antibody (mAb) development, and drives the general trend in the immunotherapy space toward the use of fully human mAbs for therapeutic applications. The YUMAB® antibody platform provides rapid, reliable and robust development of “state-of-the-art” and “next-generation” fully human antibodies. The technologies base on more than 28 years of continuous research and development of our founders, who are well recognized scientific experts in the field of recombinant antibody technologies and who have an outstanding track-record in academic and industrial research. YUMAB provides optimized antibody development solutions for: i) discovery & development of novel, fully human antibodies, ii) antibody engineering & humanization, and iii) personalized & custom libraries Key features of the YUMAB® platform are: i) world’s best, naturally derived, universal, human antibody libraries (>10e11) ii) powerful in vitro selection technologies including on-cells-selection for difficult targets iii) large scale screening platforms iv) comprehensive portfolio of antibody engineering & humanization technologies v) compatibility to all therapeutic antibody formats YUMAB provides fee for service solutions with attractive pricing and flexible license models & options as well as collaborative projects. YUMAB’s research & development unit performs internal pipeline and partnered projects ranging from the development of novel antibody therapeutics to the discovery to novel targets technologies. Our mission is to make the best human antibody technologies available for the early development to accelerate translation of research from bench to bedsite.